Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Below Fifty Day Moving Average of $14.21

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$14.21 and traded as low as C$14.21. Cipher Pharmaceuticals shares last traded at C$14.50, with a volume of 53,800 shares traded.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CPH. Stifel Canada raised Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th. Stifel Nicolaus raised shares of Cipher Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from C$9.50 to C$16.00 in a research note on Tuesday, August 13th. Finally, Leede Financial cut shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th.

Cipher Pharmaceuticals Stock Down 2.0 %

The stock has a market capitalization of C$371.06 million, a price-to-earnings ratio of 11.79 and a beta of 1.25. The firm has a 50-day moving average of C$14.21 and a 200 day moving average of C$10.57. The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its earnings results on Thursday, August 8th. The company reported C$0.16 EPS for the quarter, beating the consensus estimate of C$0.15 by C$0.01. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. The company had revenue of C$7.26 million during the quarter, compared to analysts’ expectations of C$7.52 million. On average, sell-side analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.4156977 earnings per share for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.